StockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM)

StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research note published on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts have also commented on ALIM. Maxim Group reaffirmed a hold rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Alliance Global Partners reissued a neutral rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Finally, HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price objective on the stock. in a report on Tuesday, June 25th.

Alimera Sciences Stock Performance

ALIM stock opened at $5.54 on Monday. The stock’s 50 day simple moving average is $5.55 and its 200 day simple moving average is $4.52. Alimera Sciences has a 12-month low of $2.61 and a 12-month high of $5.65. The firm has a market cap of $290.24 million, a P/E ratio of -3.53 and a beta of 1.25. The company has a current ratio of 2.79, a quick ratio of 2.62 and a debt-to-equity ratio of 1.80.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. The business had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. As a group, equities research analysts predict that Alimera Sciences will post -0.13 EPS for the current year.

Institutional Trading of Alimera Sciences

A number of institutional investors have recently made changes to their positions in the stock. Glazer Capital LLC bought a new stake in Alimera Sciences during the second quarter worth approximately $3,067,000. Gabelli Funds LLC purchased a new stake in shares of Alimera Sciences during the second quarter valued at $600,000. Renaissance Technologies LLC boosted its position in shares of Alimera Sciences by 3.9% in the 2nd quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock valued at $1,010,000 after purchasing an additional 6,900 shares during the period. Rhumbline Advisers purchased a new position in Alimera Sciences in the 2nd quarter worth about $113,000. Finally, Bank of New York Mellon Corp acquired a new stake in Alimera Sciences during the 2nd quarter worth about $344,000. 99.83% of the stock is owned by institutional investors and hedge funds.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).